{"title":"3D Printing: Advancement in Biogenerative Engineering to Combat Shortage of Organs and Bioapplicable Materials.","authors":"Arpana Parihar, Vasundhara Pandita, Avinash Kumar, Dipesh Singh Parihar, Nidhi Puranik, Tapas Bajpai, Raju Khan","doi":"10.1007/s40883-021-00219-w","DOIUrl":"10.1007/s40883-021-00219-w","url":null,"abstract":"<p><strong>Abstract: </strong>Organ or cell transplantation is medically evaluated for end-stage failure saving or extending the lives of thousands of patients who are suffering from organ failure disorders. The unavailability of adequate organs for transplantation to meet the existing demand is a major challenge in the medical field. This led to day-day-increase in the number of patients on transplant waiting lists as well as in the number of patients dying while on the queue. Recently, technological advancements in the field of biogenerative engineering have the potential to regenerate tissues and, in some cases, create new tissues and organs. In this context, major advances and innovations are being made in the fields of tissue engineering and regenerative medicine which have a huge impact on the scientific community is three-dimensional bioprinting (3D bioprinting) of tissues and organs. Besides this, the decellularization of organs and using this as a scaffold for generating new organs through the recellularization process shows promising results. This review discussed about current approaches for tissue and organ engineering including methods of scaffold designing, recent advances in 3D bioprinting, organs regenerated successfully using 3D printing, and extended application of 3D bioprinting technique in the field of medicine. Besides this, information about commercially available 3D printers has also been included in this article.</p><p><strong>Lay summary: </strong>Today's need for organs for the transplantation process in order to save a patient's life or to enhance the survival rate of diseased one is the prime concern among the scientific community. Recent, advances in the field of biogenerative engineering have the potential to regenerate tissues and create organs compatible with the patient's body. In this context, major advances and innovations are being made in the fields of tissue engineering and regenerative medicine which have a huge impact on the scientific community is three-dimensional bioprinting (3D bioprinting) of tissues and organs. Besides this, the decellularization of organs and using this as a scaffold for generating new organs through the recellularization process shows promising results. This review dealt with the current approaches for tissue and organ engineering including methods of scaffold designing, recent advances in 3D bioprinting, organs regenerated successfully using 3D printing, and extended application of 3D bioprinting technique in the field of medicine. Furthermore, information about commercially available 3D printers has also been included in this article.</p>","PeriodicalId":20936,"journal":{"name":"Regenerative Engineering and Translational Medicine","volume":"8 2","pages":"173-199"},"PeriodicalIF":2.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9222561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pre-eclampsia: a Scoping Review of Risk Factors and Suggestions for Future Research Direction.","authors":"Kiara Lee, Lynae Brayboy, Anubhav Tripathi","doi":"10.1007/s40883-021-00243-w","DOIUrl":"10.1007/s40883-021-00243-w","url":null,"abstract":"<p><strong>Abstract: </strong>Most of maternal deaths are preventable, and one-quarter of maternal deaths are due to pre-eclampsia and eclampsia. Prenatal screening is essential for detecting and managing pre-eclampsia. However, pre-eclampsia screening is solely based on maternal risk factors and has low (< 5% in the USA) detection rates. This review looks at pre-eclampsia from engineering, public health, and medical points of view. First, pre-eclampsia is defined clinically, and the biological basis of established risk factors is described. The multiple theories behind pre-eclampsia etiology should serve as the scientific basis behind established risk factors for pre-eclampsia; however, African American race does not have sufficient evidence as a risk factor. We then briefly describe predictive statistical models that have been created to improve screening detection rates, which use a combination of biophysical and biochemical biomarkers, as well as aspects of patient medical history as inputs. Lastly, technologies that aid in advancing pre-eclampsia screening worldwide are explored. The review concludes with suggestions for more robust pre-eclampsia research, which includes diversifying study sites, improving biomarker analytical tools, and for researchers to consider studying patients before they become pregnant to improve pre-eclampsia detection rates. Additionally, researchers must acknowledge the systemic racism involved in using race as a risk factor and include qualitative measures in study designs to capture the effects of racism on patients.</p><p><strong>Lay summary: </strong>Pre-eclampsia is a pregnancy-specific hypertensive disorder that can affect almost every organ system and complicates 2-8% of pregnancies globally. Here, we focus on the biological basis of the risk factors that have been identified for the condition. African American race currently does not have sufficient evidence as a risk factor and has been poorly studied. Current clinical methods poorly predict a patient's likelihood of developing pre-eclampsia; thus, researchers have made statistical models that are briefly described in this review. Then, low-cost technologies that aid in advancing pre-eclampsia screening are discussed. The review ends with suggestions for research direction to improve pre-eclampsia screening in all settings.Overall, we suggest that the future of pre-eclampsia screening should aim to identify those at risk before they become pregnant. We also suggest that the clinical standard of assessing patient risk solely on patient characteristics needs to be reevaluated, that study locations of pre-eclampsia research need to be expanded beyond a few high-income countries, and that low-cost technologies should be developed to increase access to prenatal screening.</p>","PeriodicalId":20936,"journal":{"name":"Regenerative Engineering and Translational Medicine","volume":"989 1","pages":"394-406"},"PeriodicalIF":2.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77605256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
LeNaiya Kydd, Fawaz Alalhareth, Ana Mendez, Maryann Hohn, Ami Radunskaya, Hristo Kojouharov, Justyn Jaworski
{"title":"Introduction of Plasmid to the Murine Gut via Consumption of an <i>Escherichia coli</i> Carrier and Examining the Impact of Bacterial Dosing and Antibiotics on Persistence.","authors":"LeNaiya Kydd, Fawaz Alalhareth, Ana Mendez, Maryann Hohn, Ami Radunskaya, Hristo Kojouharov, Justyn Jaworski","doi":"10.1007/s40883-022-00248-z","DOIUrl":"https://doi.org/10.1007/s40883-022-00248-z","url":null,"abstract":"<p><strong>Purpose: </strong>We examine the impacts of dosing strategies of plasmids on bacterial communities in the murine gut by measuring the quantity of plasmids in mouse feces.</p><p><strong>Methods: </strong>We fed mice carrier bacteria, <i>E. coli</i>, that contain plasmids with both a reporter gene and an antibiotic resistant gene. We varied the quantity of the plasmid-carrying bacteria and the length of time the mice consumed the bacteria. We also pretreated the gut with broad-spectrum antibiotics and used continuous antibiotic treatment to investigate selection pressure. We collected bacteria from fecal pellets to quantify the number of plasmid-carrying bacteria via plate assay.</p><p><strong>Results: </strong>Dosing regimens with plasmid-carrying bacteria resulted in a significantly increased duration of persistence of the plasmid within the gut when supplemented continuously with kanamycin during as well as after completion of bacterial dosing. The carrier bacteria concentration influenced the short-term abundance of carrier bacteria.</p><p><strong>Conclusion: </strong>We evaluated the persistence of plasmid-carrying bacteria in the murine gut over time using varying dosage strategies. In future work, we will study how bacterial diversity in the gut impacts the degree of plasmid transfer and the prevalence of plasmid-carrying bacteria over time.</p><p><strong>Lay summary: </strong>Observing how plasmids persist within the gut can help us understand how newly introduced genes, including antibiotic resistance, are transmitted within the gut microbiome. In our experiments, mice were given bacteria containing a genetically engineered plasmid and were examined for the persistence of the plasmid in the gut. We found long-term persistence of the plasmid in the gut when administering antibiotics during and following dosing of the mice with bacteria carrying the plasmid. The use of higher concentrations of carrier bacteria influenced the short-term abundance of the plasmid-carrying bacteria in the gut.</p><p><strong>Description of future works: </strong>Building on evidence from these initial studies that persistence of plasmids within the gut can be regulated by the dosage strategy, we will explore future studies and models of gene uptake in the context of spatial and taxonomic control and further determine if dosing strategies alter the compositional diversity of the gut microbiome.</p><p><strong>Graphical abstract: </strong></p>","PeriodicalId":20936,"journal":{"name":"Regenerative Engineering and Translational Medicine","volume":" ","pages":"489-497"},"PeriodicalIF":2.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40580889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Potential for Stem Cell-Based Therapy in the Road of Treatment for Neurological Disorders Secondary to COVID-19.","authors":"Babak Arjmand, Peyvand Parhizkar Roudsari, Sepideh Alavi-Moghadam, Mostafa Rezaei-Tavirani, Akram Tayanloo-Beik, Neda Mehrdad, Hossein Adibi, Bagher Larijani","doi":"10.1007/s40883-021-00234-x","DOIUrl":"https://doi.org/10.1007/s40883-021-00234-x","url":null,"abstract":"<p><strong>Abstract: </strong>The severe acute respiratory syndrome coronavirus 2 has led to the worldwide pandemic named coronavirus disease 2019 (COVID-19). It has caused a significant increase in the number of cases and mortalities since its first diagnosis in December 2019. Although COVID-19 primarily affects the respiratory system, neurological involvement of the central and peripheral nervous system has been also reported. Herein, the higher risk of neurodegenerative diseases in COVID-19 patients in future is also imaginable. Neurological complications of COVID-19 infection are more commonly seen in severely ill individuals; but, earlier diagnosis and treatment can lead to better long-lasting results. In this respect, stem cell biotechnologies with considerable self-renewal and differentiation capacities have experienced great progress in the field of neurological disorders whether in finding out their underlying processes or proving them promising therapeutic approaches. Herein, many neurological disorders have been found to benefit from stem cell medicine strategies. Accordingly, in the present review, the authors are trying to discuss stem cell-based biotechnologies as promising therapeutic options for neurological disorders secondary to COVID-19 infection through reviewing neurological manifestations of COVID-19 and current stem cell-based biotechnologies for neurological disorders.</p><p><strong>Lay summary: </strong>Due to the substantial burden of neurological disorders in the health, economic, and social system of society, the emergence of neurological manifestations following COVID-19 (as a life-threatening pandemic) creates the need to use efficient and modern methods of treatment. Since stem cell-based methods have been efficient for a large number of neurological diseases, it seems that the use of mentioned methods is also effective in the process of improving neurological disorders caused by COVID-19. Hereupon, the current review aims to address stem cell-based approaches as treatments showing promise to neurological disorders related to COVID-19.</p>","PeriodicalId":20936,"journal":{"name":"Regenerative Engineering and Translational Medicine","volume":"8 3","pages":"355-369"},"PeriodicalIF":2.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39852113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Angliana Chouw, Tiana Milanda, Cynthia Retna Sartika, Marsya Nilam Kirana, Danny Halim, Ahmad Faried
{"title":"Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19.","authors":"Angliana Chouw, Tiana Milanda, Cynthia Retna Sartika, Marsya Nilam Kirana, Danny Halim, Ahmad Faried","doi":"10.1007/s40883-021-00202-5","DOIUrl":"https://doi.org/10.1007/s40883-021-00202-5","url":null,"abstract":"<p><strong>Abstract: </strong>The COVID-19 disease, which is caused by the novel coronavirus, SARS-CoV-2, has affected the world by increasing the mortality rate in 2020. Currently, there is no definite treatment for COVID-19 patients. Several clinical trials have been proposed to overcome this disease and many are still under investigation. In this review, we will be focusing on the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. Fever, cough, headache, dizziness, and fatigue are the common clinical manifestations in COVID-19 patients. In mild and severe cases, cytokines are released hyper-actively which causes a cytokine storm leading to acute respiratory distress syndrome (ARDS). In order to maintain the lung microenvironment in COVID-19 patients, MSCs are used as cell-based therapy approaches as they can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote endogenous repair. Besides, MSCs have shown minimal expression of ACE2 or TMPRSS2, and hence, MSCs are free from SARS-CoV-2 infection. Numerous clinical studies have started worldwide and demonstrated that MSCs have great potential for ARDS treatment in COVID-19 patients. Preliminary data have shown that MSCs and MSC-derived secretome appear to be promising in the treatment of COVID-19.</p><p><strong>Lay summary: </strong>The COVID-19 disease is an infection disease which affects the world in 2020. Currently, there is no definite treatment for COVID-19 patients. However, several clinical trials have been proposed to overcome this disease and one of them is using mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. During the infection, cytokines are released hyper-actively which causes a cytokine storm. MSCs play an important role in maintaining the lung microenvironment in COVID-19 patients. They can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote the endogenous repair. Therefore, it is important to explore the clinical trial in the world for treating the COVID-19 disease using MSCs and MSC-derived secretome.</p>","PeriodicalId":20936,"journal":{"name":"Regenerative Engineering and Translational Medicine","volume":"8 1","pages":"43-54"},"PeriodicalIF":2.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40883-021-00202-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25482052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Holly Ryan, Daniel Bister, Sophia A Holliday, Jessica Boehlein, Aljae Lewis, Justin Silberman, Josephine B Allen, Erika Moore
{"title":"Ancestral Background Is Underreported in Regenerative Engineering.","authors":"Holly Ryan, Daniel Bister, Sophia A Holliday, Jessica Boehlein, Aljae Lewis, Justin Silberman, Josephine B Allen, Erika Moore","doi":"10.1007/s40883-021-00237-8","DOIUrl":"https://doi.org/10.1007/s40883-021-00237-8","url":null,"abstract":"<p><strong>Purpose: </strong>The ancestral background of human cells may play a role in cells' behavior and response to therapeutic interventions in vitro. We investigate the prevalence of ancestry reporting in current biological research and suggest that increased reporting would be beneficial to the field.</p><p><strong>Methods: </strong>Articles published over a six-month period in ten different journals were reviewed for their use of human primary cells and immortalized cell lines, and were analyzed based on whether or not the ancestral or ethnic information of cell donors was ascertainable.</p><p><strong>Results: </strong>The vast majority of literature published in the journals and timeframe we investigated did not report on the ancestral or ethnic origins of the human cells used.</p><p><strong>Conclusion: </strong>There is currently a substantial lack of reporting on the ancestral background of human cells used for research. We suggest that increased ancestral reporting should be implemented in order to improve the development of precision medicine.</p><p><strong>Lay summary: </strong>Many diseases affect patients of different ancestral backgrounds in a variety of ways. In this perspective article, we raise the concern that, since many scientists do not consider ancestry when designing their studies, their results may not apply to all patients. We use data to show that very few scientists report on the ancestry of the donors who contribute cells and tissues to their research. We suggest that broader reporting on donor ancestry would improve biomedical research and would help doctors to personalize treatments for their patients.Future work includes further increasing awareness of the importance of including ancestry as a variable in experimental design, as well as promoting increased reporting on ancestry in the research community.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40883-021-00237-8.</p>","PeriodicalId":20936,"journal":{"name":"Regenerative Engineering and Translational Medicine","volume":" ","pages":"499-503"},"PeriodicalIF":2.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39624511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kenyatta S Washington, Nikoo Saveh Shemshaki, Cato T Laurencin
{"title":"The Role of Nanomaterials and Biological Agents on Rotator Cuff Regeneration.","authors":"Kenyatta S Washington, Nikoo Saveh Shemshaki, Cato T Laurencin","doi":"10.1007/s40883-020-00171-1","DOIUrl":"https://doi.org/10.1007/s40883-020-00171-1","url":null,"abstract":"<p><p>The rotator cuff is a musculotendon unit responsible for movement in the shoulder. Rotator cuff tears represent a significant number of musculoskeletal injuries in the adult population. In addition, there is a high incidence of retear rates due to various complications within the complex anatomical structure and the lack of proper healing. Current clinical strategies for rotator cuff augmentation include surgical intervention with autograft tissue grafts and beneficial impacts have been shown, but challenges still exist because of limited supply. For decades, nanomaterials have been engineered for the repair of various tissue and organ systems. This review article provides a thorough summary of the role nanomaterials, stem cells and biological agents have played in rotator cuff repair to date and offers input on next generation approaches for regenerating this tissue.</p>","PeriodicalId":20936,"journal":{"name":"Regenerative Engineering and Translational Medicine","volume":"7 4","pages":"440-449"},"PeriodicalIF":2.6,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40883-020-00171-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39802555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paulos Y Mengsteab, Joseph Freeman, Mohammed A Barajaa, Lakshmi S Nair, Cato T Laurencin
{"title":"Ligament Regenerative Engineering: Braiding Scalable and Tunable Bioengineered Ligaments Using a Bench-Top Braiding Machine.","authors":"Paulos Y Mengsteab, Joseph Freeman, Mohammed A Barajaa, Lakshmi S Nair, Cato T Laurencin","doi":"10.1007/s40883-020-00178-8","DOIUrl":"10.1007/s40883-020-00178-8","url":null,"abstract":"<p><p>Anterior cruciate ligament (ACL) injuries are common sports injuries that typically require surgical intervention. Autografts and allografts are used to replace damaged ligaments. The drawbacks of autografts and allografts, which include donor site morbidity and variability in quality, have spurred research in the development of bioengineered ligaments. Herein, the design and development of a cost-effective bench-top 3D braiding machine that fabricates scalable and tunable bioengineered ligaments is described. It was demonstrated that braiding angle and picks per inch can be controlled with the bench-top braiding machine. Pore sizes within the reported range needed for vascularization and bone regeneration are demonstrated. By considering a one-to-one linear relationship between cross-sectional area and peak load, the bench-top braiding machine can theoretically fabricate bioengineered ligaments with a peak load that is 9× greater than the human ACL. This bench-top braiding machine is generalizable to all types of yarns and may be used for regenerative engineering applications.</p>","PeriodicalId":20936,"journal":{"name":"Regenerative Engineering and Translational Medicine","volume":"7 4","pages":"524-532"},"PeriodicalIF":2.6,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734580/pdf/nihms-1635563.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39802556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Stephanie A Maynard, Charles W Winter, Eoghan M Cunnane, Molly M Stevens
{"title":"Advancing cell instructive biomaterials through increased understanding of cell receptor spacing and material surface functionalization.","authors":"Stephanie A Maynard, Charles W Winter, Eoghan M Cunnane, Molly M Stevens","doi":"10.1007/s40883-020-00180-0","DOIUrl":"10.1007/s40883-020-00180-0","url":null,"abstract":"<p><p>Regenerative medicine is aimed at restoring normal tissue function and can benefit from the application of tissue engineering and nano-therapeutics. In order for regenerative therapies to be effective, the spatiotemporal integration of tissue engineered scaffolds by the native tissue, and the binding/release of therapeutic payloads by nano-materials, must be tightly controlled at the nanoscale in order to direct cell fate. However, due to a lack of insight regarding cell-material interactions at the nanoscale and subsequent downstream signaling, the clinical translation of many regenerative therapies is limited due to poor material integration, rapid clearance and complications such as graft-versus-host disease. This review paper is intended to outline our current understanding of cell-material interactions with the aim of highlighting potential areas for knowledge advancement or application in the field of regenerative medicine. This is achieved by reviewing the nanoscale organization of key cell surface receptors, the current techniques used to control the presentation of cell-interactive molecules on material surfaces, as well as the most advanced techniques for characterizing the interactions that occur between cell surface receptors and materials intended for use in regenerative medicine.</p>","PeriodicalId":20936,"journal":{"name":"Regenerative Engineering and Translational Medicine","volume":"7 4","pages":"553-547"},"PeriodicalIF":2.2,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39645397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bennett E. Propp, C. Uyeki, Michael R. Mancini, Benjamin C. Hawthorne, M. Mccarthy, A. Mazzocca
{"title":"A Review of Biological Augmentation for Rotator Cuff Repair: a Single Laboratory’s History","authors":"Bennett E. Propp, C. Uyeki, Michael R. Mancini, Benjamin C. Hawthorne, M. Mccarthy, A. Mazzocca","doi":"10.1007/s40883-021-00240-z","DOIUrl":"https://doi.org/10.1007/s40883-021-00240-z","url":null,"abstract":"","PeriodicalId":20936,"journal":{"name":"Regenerative Engineering and Translational Medicine","volume":"22 1","pages":"377 - 383"},"PeriodicalIF":2.6,"publicationDate":"2021-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81625856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}